Categories: News

BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences

RALEIGH, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Executive Vice President and Chief Financial Officer, will present and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference taking place on September 13-15 and the Cantor Fitzgerald Global Healthcare Conference taking place on September 27-30.

The fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference will be available to conference registrants on-demand beginning Monday, September 13, 2021, at 7:00 AM ET.

Details for the live presentation at the Cantor Fitzgerald Global Healthcare Conference can be found below.

Date: Tuesday, September 28, 2021
Time: 9:20 AM ET
Format: Fireside chat
Webcast: https://wsw.com/webcast/cantor12/bdsi/2064020

Institutional investors interested in a one-on-one meeting with BDSI management should contact their respective H.C. Wainwright or Cantor Fitzgerald institutional sales representative.

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI’s marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

© 2021 BioDelivery Sciences International, Inc.  All rights reserved.

Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Staff

Recent Posts

Mobile-health Network Solutions Announces Closing of Initial Public Offering

SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“MNDR” or “the Company”), a…

7 hours ago

Biomerica Reports Third Quarter 2024 Financial Results

Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst…

7 hours ago

American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

SAN FRANCISCO, April 12, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…

7 hours ago

Better Choice Company, Inc. Announces Fourth Quarter and Full Year 2023 Results

Gross Margin Improved 300 basis points to 31% Year-Over-Year Adjusted EBITDA Grew 30% Year-Over-Year EPS…

7 hours ago

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link…

7 hours ago